openPR Logo
Press release

Ovarian Cancer Drugs Market - Granular View of The Market from Various End-Use Segments

02-05-2018 07:20 AM CET | Associations & Organizations

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Ovarian Cancer Drugs Market - Granular View of The Market from

Ovarian cancer is a term attributed to the uncommon type of cancer that arises in the ovary of a woman from different types of cells. Ovarian cancer is caused due to the mutagenic changes in DNA. Inherited mutations in genes are also responsible for ovarian cancer. The risk of developing ovarian cancer is high if a woman has inherited mutations in the BRCA1 and BRCA2 genes. The most common type of ovarian cancer is epithelial ovarian cancer (EOC), which arises from the epithelium of the ovary. Ovarian cancer is regarded as one of the most common types of cancer among women. It accounts for more deaths than any other cancer of the female reproductive system, while it ranks 5th in overall women deaths due to cancer. This type of cancer is rarely diagnosed at an early stage, making treatment at an advanced stage difficult.

Obtain Brochure@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34061

According to American Cancer Society estimates, risk of any woman acquiring ovarian cancer in her lifetime is 1 in 75, while her chance of death due to ovarian cancer is 1 in 100. Ovarian cancer is more prevalent among elderly women, making women over 55 a high-risk population. Women in this age group have the lowest survival rate as well. Surgical procedures are employed for the treatment of both early and advanced stages of ovarian cancer. According to American Cancer Society estimates, about 22,440 women are expected to be diagnosed with ovarian cancer in the U.S., while about 14,080 women deaths would be attributed to ovarian cancer in 2017.

Ovarian cancer and its rising incidence rate is a growing concern worldwide. Market players that are currently engaged in the development of drugs and chemotherapies for management of ovarian cancer. The global ovarian cancer drugs market is expected to be driven by large number of therapeutics in developmental stage and competition among market players in terms of efficacy and cost of therapies. The patent expiry of several leading drugs could also potentially impact this market by encouraging the entry of new players. These changing dynamics will impact the ovarian cancer market during the forecast period. The global ovarian cancer drugs market holds immense potential and is anticipated to grow rapidly.

Continuous research and development to provide efficient therapeutic intervention for a host of diseases boosts the growth of the ovarian cancer drugs market. Several ovarian cancer drugs are in clinical phase and expected to drive the market in the near future. For instance, Merck, Pfizer, and Syndax Pharmaceuticals, Inc. have signed an exclusive agreement to study two investigational agents or drugs for treatment of ovarian cancer. This study includes the drugs Avelumab and entinostat evaluated for efficacy as combination therapy for ovarian cancer.

Obtain Report Details @ https://www.transparencymarketresearch.com/ovarian-cancer-drugs-market.html

The global ovarian cancer drugs market can be segmented based on tumor type, drug class, distribution channel, and region. In terms of tumor type, the market can be classified into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, and sex cord-stromal tumor. Based on drug class, the global ovarian cancer drugs market can be categorized into alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, antineoplastics, and others. In terms of distribution channel, the market can be divided into hospital pharmacies, drug stores, online pharmacies, and others. In terms of region, the global ovarian cancer drugs market can be segmented into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America. Major players in the global ovarian cancer drugs market are Allergan plc, Pfizer, Inc., Merck KGaA, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson, Syndax Pharmaceuticals, Inc., Clovis Oncology, and others.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact TMR

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ovarian Cancer Drugs Market - Granular View of The Market from Various End-Use Segments here

News-ID: 930178 • Views: 174

More Releases from Transparency Market Research

Effervescent Packaging Market: Rising Demand for Fast Dissolving Drug Delivery S …
A recent study by Transparency Market Research (TMR) has detected that the global effervescent packaging market is heavily dependent on product innovation and in the near future, a number of strategic mergers and acquisitions will follow that will define the leader. Some of the key companies currently operating in the global effervescent packaging market are Sanner GmbH, Oracle Packaging, Inc., Unither Pharmaceuticals, Romaco Pharmatechnik GmbH, Parekhplast India Ltd., Tower Laboratories
Form-fill-seal Machines Market: Prosperity of Packaged Food and Beverage Industr …
An up-to-date study by Transparency Market Research (TMR) reveals that the global form-fill-seal machines market is fragmented in nature, although Robert Bosch GmbH does hold a position of strength, accounting for 11% of the overall market shares in 2017. Some of the other key players identified by the report who are making a mark in the global form-fill-seal machines market are: Tokyo Automatic Machinery Works Ltd., Uflex Ltd., Hayssen Flexible
Chatbot Market: Key Players and Production Information analysis
A 27.8% CAGR (Compound Annual Growth Rate) is set to mark the forecast period between 2016 and 2024, as per a Transparency Market Research (TMR) report. And, as per the analysts at TMR , some of the factors that the growth shall be attributed to are increasing popularity and adoption of Artificial Intelligence (AI) across industry verticals, including end-users, and innovation marking the landscape in a big way. This will
Digital Voice Recorder Market: Rising Allocations OnanalysisAnd Innovation
With the presence of a copious number of companies, the global market for digital voice recorder is fragmented with intense competition. In this scenario, top companies are aggressively engaged in technological advancements to serve ever-changing consumer demand, for which they are investing heavily in this market. In the years ahead, these players are likely to concentrate on regional expansion, for which they might resort to business alliances with regional players. Key

All 5 Releases


More Releases for Ovarian

Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Polycystic Ovarian Syndrome - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Polycystic Ovarian Syndrome - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms
Ovarian Cancer Drugs Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Ovarian Cancer Drugs Market Report : 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-ovarian-cancer-drugs-market-report-2017-1541150 In this report, the United States Ovarian Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United
Ovarian Cancer - Pipeline Review, H1 2017
Report Hive Market Research Released a New Research Report of 2027 pages on Title " Ovarian Cancer - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies. Ovarian Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Ovarian cancer is any cancerous growth that may occur in different
Ovarian Cancer Drug Pipeline Review H1 2017
Pharmaceutical guide Ovarian Cancer - Pipeline Review H1 2017 guide reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. Report also provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Report provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in